Mantle cell lymphoma: evolving management strategies

被引：150

作者：

Campo, Elias ^{[1
]}

Rule, Simon ^{[2
,3
,4
]}

机构：

[1] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Pathol, Hematopathol Sect,Hosp Clin, Barcelona, Spain

[2] Univ Plymouth, Peninsula Sch Med, Plymouth PL6 8DH, Devon, England

[3] Univ Plymouth, Peninsula Sch Dent, Plymouth PL6 8DH, Devon, England

[4] Derriford Hosp, Plymouth PL6 8DH, Devon, England

来源：

BLOOD | 2015年 / 125卷 / 01期

关键词：

RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PROSPECTIVE RANDOMIZED-TRIAL; COOPERATIVE-ONCOLOGY-GROUP; SINGLE-AGENT LENALIDOMIDE; PROGRESSION-FREE SURVIVAL; PHASE-II MULTICENTER; HIGH-DOSE CYTARABINE; B-CELL; MAINTENANCE RITUXIMAB; 1ST-LINE TREATMENT;

D O I：

10.1182/blood-2014-05-521898

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma that generally affects older individuals and continues to have one of the worst outcomes of all the lymphomas. Over the last decade, there has been a widespread adoption of cytarabine-based therapy in younger patients, and the incorporation of rituximab into chemotherapeutic regimens has become an evidence-based standard of care. However MCL remains a largely incurable disease, and following relapse, it can be a challenge to manage. Although it is possible to define prognosis reliably, there are, as yet, no clear diagnostic or response-adjusted parameters that can help to guide therapeutic decisions. However, there are a number of highly active targeted therapies that are moving into the clinic that are set to transform the therapeutic paradigm for this disease in the very near future. This review will explore the molecular pathogenesis of MCL and the current and evolving therapeutic strategies for this disease.

引用

页码：48 / 55

页数：8

共 87 条

[1]

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2]

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia [J].

Agathocleous, Agathoclis ;

Rohatiner, Ama ;

Rule, Simon ;

Hunter, Hannah ;

Kerr, Jonathan Paul ;

Neeson, Susan M. ;

Matthews, Janet ;

Strauss, Sandra ;

Montoto, Silvia ;

Johnson, Peter ;

Radford, John ;

Lister, Andrew .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (04) :346-353

[3]

Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma [J].

Andersen, Niels S. ;

Pedersen, Lone B. ;

Laurell, Anna ;

Elonen, Erkki ;

Kolstad, Arne ;

Boesen, Anne Marie ;

Pedersen, Lars M. ;

Lauritzsen, Grete F. ;

Ekanger, Roald ;

Nilsson-Ehle, Herman ;

Nordstrom, Marie ;

Freden, Susanne ;

Jerkeman, Mats ;

Eriksson, Mikael ;

Vaart, Jaan ;

Malmer, Beatrice ;

Geisler, Christian H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4365-4370

[4]

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study [J].

Ansell, Stephen M. ;

Tang, Hui ;

Kurtin, Paul J. ;

Koenig, Patricia A. ;

Inwards, David J. ;

Shah, Keith ;

Ziesmer, Steven C. ;

Feldman, Andrew L. ;

Rao, Radha ;

Gupta, Mamta ;

Erlichman, Charles ;

Witzig, Thomas E. .

LANCET ONCOLOGY, 2011, 12 (04) :361-368

[5]

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group [J].

Arranz, Reyes ;

Garcia-Noblejas, Ana ;

Grande, Carlos ;

Cannata-Ortiz, Jimena ;

Sanchez, Jose J. ;

Garcia-Marco, Jose-Antonio ;

Alaez, Concepcion ;

Perez-Calvo, Javier ;

Martinez-Sanchez, Pilar ;

Sanchez-Gonzalez, Blanca ;

Canales, Miguel-Angel ;

Conde, Eulogio ;

Martin, Alejandro ;

Arranz, Eva ;

Terol, Maria-Jose ;

Salar, Antonio ;

Caballero, Dolores .

HAEMATOLOGICA, 2013, 98 (10) :1563-1570

[6]

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma [J].

Baiocchi, Robert A. ;

Alinari, Lapo ;

Lustberg, Mark E. ;

Lin, Thomas S. ;

Porcu, Pierluigi ;

Li, Xiaobai ;

Johnston, Jeffrey S. ;

Byrd, John C. ;

Blum, Kristie A. .

CANCER, 2011, 117 (11) :2442-2451

[7]

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma [J].

Baran-Marszak, Fanny ;

Boukhiar, Mohand ;

Harel, Stephanie ;

Laguillier, Christelle ;

Roger, Claudine ;

Gressin, Remy ;

Martin, Antoine ;

Fagard, Remi ;

Varin-Blank, Nadine ;

Ajchenbaum-Cymbalista, Florence ;

Ledoux, Dominique .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11) :1865-1872

[8]

Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma [J].

Bauwens, D ;

Maerevoet, M ;

Michaux, L ;

Théate, I ;

Hagemeijer, A ;

Stul, M ;

Danse, E ;

Costantini, S ;

Vannuffel, P ;

Straetmans, N ;

Vekemans, MC ;

Deneys, V ;

Ferrant, A ;

Van Den Neste, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (03) :338-340

[9]

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma [J].

Bea, Silvia ;

Valdes-Mas, Rafael ;

Navarro, Alba ;

Salaverria, Itziar ;

Martin-Garcia, David ;

Jares, Pedro ;

Gine, Eva ;

Pinyol, Magda ;

Royo, Cristina ;

Nadeu, Ferran ;

Conde, Laura ;

Juan, Manel ;

Clot, Guillem ;

Vizan, Pedro ;

Di Croce, Luciano ;

Puente, Diana A. ;

Lopez-Guerra, Monica ;

Moros, Alexandra ;

Roue, Gael ;

Aymerich, Marta ;

Villamor, Neus ;

Colomo, Lluis ;

Martinez, Antonio ;

Valera, Alexandra ;

Martin-Subero, Jose I. ;

Amador, Virginia ;

Hernandez, Luis ;

Rozman, Maria ;

Enjuanes, Anna ;

Forcada, Pilar ;

Muntanola, Ana ;

Hartmann, Elena M. ;

Calasanz, Maria J. ;

Rosenwald, Andreas ;

Ott, German ;

Hernandez-Rivas, Jesus M. ;

Klapper, Wolfram ;

Siebert, Reiner ;

Wiestner, Adrian ;

Wilson, Wyndham H. ;

Colomer, Dolors ;

Lopez-Guillermo, Armando ;

Lopez-Otin, Carlos ;

Puente, Xose S. ;

Campo, Elias .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (45) :18250-18255

[10]

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma [J].

Beaven, Anne W. ;

Shea, Thomas C. ;

Moore, Dominic T. ;

Feldman, Tatyana ;

Ivanova, Anastasia ;

Ferraro, Madlyn ;

Ford, Peggy ;

Smith, Judith ;

Goy, Andre .

LEUKEMIA & LYMPHOMA, 2012, 53 (02) :254-258

← 1 2 3 4 5 6 7 8 9 →